^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Factor XI inhibitor

    Associations

    News

    Trials
    25d
    A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (clinicaltrials.gov)
    P2, N=450, Recruiting, Sirius Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enoxaparin sodium
    28d
    ROXI-CATH: A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (clinicaltrials.gov)
    P2, N=195, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    ROXI-PALISADE: Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease (clinicaltrials.gov)
    P3, N=7050, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial • Adverse events
    1m
    A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Sirius Therapeutics Co., Ltd.
    New P2 trial
    2ms
    ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (clinicaltrials.gov)
    P3, N=2000, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    2ms
    MAGNOLIA: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (clinicaltrials.gov)
    P3, N=417, Active, not recruiting, Anthos Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=1020 --> 417
    Enrollment closed • Enrollment change
    |
    Fragmin (dalteparin sodium)
    3ms
    ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (clinicaltrials.gov)
    P2, N=1200, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (clinicaltrials.gov)
    P3, N=2000, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    aspirin
    4ms
    To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Suzhou Alphamab Co., Ltd.
    New P1/2 trial
    5ms
    To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension (clinicaltrials.gov)
    P1, N=60, Recruiting, Suzhou Alphamab Co., Ltd.
    New P1 trial
    5ms
    Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (clinicaltrials.gov)
    P2, N=241, Active, not recruiting, Suzhou Alphamab Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    enoxaparin sodium
    5ms
    ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (clinicaltrials.gov)
    P2, N=1200, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial